SCHEMBL20004113

SCHEMBL20004113

Fc1ccc(N2Cc3ccccc3C2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 5/20 0.51
GRIN3B O60391 5/20 0.51
GRIN1 Q05586 5/20 0.51
GRIN2A Q12879 5/20 0.51
GRIN2B Q13224 5/20 0.51
GRIN2C Q14957 5/20 0.51
GRIN3A Q8TCU5 5/20 0.51
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HTT P42858 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375629 0.78 GRIN2D (0.79) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL17191285 0.78 GRIN2D (0.79) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL23019651 0.78 GRIN2D (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22466096 0.78 GRIN2D (0.79) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13285112 0.75 MAPT (0.51) SMN1; SMN2ALDH1A1MAPTHSD17B10SLC27A1
SCHEMBL15857987 0.74 TDO2 (0.56) SMN1; SMN2KMT2ARAB9AALDH1A1DHFR
SCHEMBL15774102 0.74 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13284677 0.73 MAPT (0.53) ALDH1A1MAPTSLC27A1DHFRGPR119
SCHEMBL19998631 0.73 GRIN2D (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7480559 0.72 GRIN2D (0.76) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 US disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 EP disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 US disclosed
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-06-11 US disclosed
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-10-24 US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 GRIN2D 4713/4885GRIN3B 4807/4885GRIN1 4469/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 GRIN2D 4422/4885GRIN3B 4681/4885GRIN1 3754/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 GRIN2D 4422/4885GRIN3B 4681/4885GRIN1 3754/4885
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 GRIN2D 4532/4885GRIN3B 4671/4885GRIN1 3671/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 GRIN2D 4713/4885GRIN3B 4807/4885GRIN1 4469/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 GRIN2D 4422/4885GRIN3B 4681/4885GRIN1 3754/4885
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 GRIN2D 4422/4885GRIN3B 4681/4885GRIN1 3754/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 GRIN2D 4422/4885GRIN3B 4681/4885GRIN1 3754/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 GRIN2D 4422/4885GRIN3B 4681/4885GRIN1 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.